Form 4: Accuray CCO Paul Miele Receives 650,000 RSU Grant

Accuray Incorporated's Chief Commercial Officer, Paul Miele, was granted 650,000 restricted stock units as part of an equity incentive plan.

Summary

• Paul Miele, SVP and Chief Commercial Officer of Accuray Inc., was awarded 650,000 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of common stock upon vesting.
• The grant has a zero-dollar exercise price.
• The vesting schedule is set over a four-year period, with the first 25% vesting on April 30, 2027, and the remainder vesting in equal annual installments thereafter.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding executive compensation, which is neutral in terms of immediate operational impact.

Positives

• The equity grant aligns the interests of the Chief Commercial Officer with long-term shareholder value creation.
• The multi-year vesting schedule serves as a retention mechanism for key executive talent.

Negatives

• The issuance of 650,000 RSUs will result in future shareholder dilution upon the eventual conversion to common stock.

Risks

• Potential for future dilution of existing equity holders.
• Executive retention risk if performance targets or market conditions impact the value of the equity incentives.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an executive equity grant.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice in the medical device sector to attract and retain senior leadership, particularly for roles focused on commercial growth and market expansion.

Comparison to Industry Standards

• The use of multi-year vesting schedules for executive RSU grants is consistent with standard corporate governance practices among mid-cap medical technology companies.
• The grant size is commensurate with typical compensation packages for C-suite executives in the healthcare equipment industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the vesting and issuance of the underlying common stock.

Next Steps

• Vesting of the first tranche of RSUs on April 30, 2027.

Key Dates

Keywords

Accuray, ARAY, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Executive Compensation